MX2023000353A - Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas. - Google Patents

Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.

Info

Publication number
MX2023000353A
MX2023000353A MX2023000353A MX2023000353A MX2023000353A MX 2023000353 A MX2023000353 A MX 2023000353A MX 2023000353 A MX2023000353 A MX 2023000353A MX 2023000353 A MX2023000353 A MX 2023000353A MX 2023000353 A MX2023000353 A MX 2023000353A
Authority
MX
Mexico
Prior art keywords
dengue
virus
constructs
compositions
den
Prior art date
Application number
MX2023000353A
Other languages
English (en)
Inventor
Dan T Stinchcomb
Claire Kinney
Richard M Kinney
Jill A Livengood
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2023000353A publication Critical patent/MX2023000353A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones, usos y manufactura de construcciones del virus del dengue y virus del dengue vivos atenuados. En ciertas modalidades, la composición puede incluir, pero no se limita a una composición tetravalente del virus del dengue. En ciertas modalidades, las composiciones pueden incluir construcciones de uno o más serotipos del virus del dengue, tales como las construcciones del virus dengue-1 (DEN-1), el virus dengue-2 (DEN-2), los virus dengue-3 (DEN-3) o dengue-4 (DEN-4). En otras modalidades, las construcciones descritas en esta invención pueden combinarse en una composición para generar una vacuna contra una o más construcciones de virus del dengue que pueden o no ser subsecuentemente pasadas a células de mamíferos.
MX2023000353A 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas. MX2023000353A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361800204P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
MX2023000353A true MX2023000353A (es) 2023-02-13

Family

ID=50678274

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2015012893A MX2015012893A (es) 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2019003602A MX2019003602A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000353A MX2023000353A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000349A MX2023000349A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000354A MX2023000354A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2015012893A MX2015012893A (es) 2013-03-15 2014-03-12 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2019003602A MX2019003602A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2023000349A MX2023000349A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.
MX2023000354A MX2023000354A (es) 2013-03-15 2015-09-14 Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas.

Country Status (32)

Country Link
US (5) US9783579B2 (es)
EP (5) EP3539565B1 (es)
JP (2) JP6818548B2 (es)
KR (3) KR20240014580A (es)
CN (5) CN111778263A (es)
AR (2) AR095598A1 (es)
AU (2) AU2014235476B2 (es)
CA (4) CA3177574A1 (es)
CR (1) CR20150569A (es)
DK (1) DK4129330T3 (es)
DO (1) DOP2015000232A (es)
EC (1) ECSP23013715A (es)
ES (2) ES2965652T3 (es)
FI (2) FI3539565T3 (es)
FR (1) FR22C1064I1 (es)
HK (1) HK1220359A1 (es)
HR (1) HRP20231581T1 (es)
HU (2) HUE061507T2 (es)
LT (1) LT4129330T (es)
MX (5) MX2015012893A (es)
MY (1) MY187796A (es)
NL (1) NL301223I2 (es)
NZ (1) NZ630869A (es)
PE (2) PE20211814A1 (es)
PH (1) PH12015502120A1 (es)
PL (1) PL3539565T3 (es)
PT (1) PT3539565T (es)
SG (3) SG10201913387XA (es)
SI (1) SI4129330T1 (es)
TW (3) TWI726312B (es)
UY (1) UY35489A (es)
WO (1) WO2014150939A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3539565T3 (pl) 2013-03-15 2023-09-25 Takeda Vaccines, Inc. Kompozycje i sposoby dla konstruktów chimerycznych wirusa dengi w szczepionkach
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
MY194650A (en) * 2015-11-27 2022-12-09 Km Biologics Co Ltd Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes
EP3442571A1 (en) 2016-04-13 2019-02-20 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2020051334A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276941A (en) 1975-12-23 1977-06-28 Ito Masato Method of conversing infrared rays
US4810092A (en) 1986-02-21 1989-03-07 Midac Corporation Economical spectrometer unit having simplified structure
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
ATE310824T1 (de) 1991-09-19 2005-12-15 Chimäre und/oder wachstumsgehemmte flaviviren
JPH05276941A (ja) 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
AU716676B2 (en) 1995-05-24 2000-03-02 Hawaii Biotech, Inc. Subunit vaccine against flavivirus infection
AU6093296A (en) * 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
ATE314476T1 (de) 1997-10-08 2006-01-15 Us Gov Health & Human Serv Chimärer impfstoff gegen das zeckenenzephalitis virus
CA2331368C (en) 1998-06-04 2009-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
WO2001039802A1 (en) * 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
ES2374131T3 (es) 2000-02-16 2012-02-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Flavivirus quiméricos avirulentos e inmunógenos.
DE60040652D1 (de) * 2000-05-30 2008-12-11 Univ Mahidol Attenuierte Stammen von Denguevirus und ihre Verwendungen in Impfstoffzusammensetzungen
AU2002309508A1 (en) 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
ATE475706T1 (de) 2005-06-17 2010-08-15 Sanofi Pasteur Abgeschwächter dengue-serotyp-2-stamm
AU2006257610B2 (en) * 2005-06-17 2012-11-15 Centers For Disease Control And Prevention Dengue serotype 1 attenuated strain
KR20070017759A (ko) 2005-08-08 2007-02-13 삼성전자주식회사 초해상 정보 저장 매체, 기록/재생 장치 및 기록/재생 방법
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
WO2008022196A2 (en) * 2006-08-15 2008-02-21 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health Andhuman Services, The Development of dengue virus vaccine components
WO2009048658A2 (en) 2007-07-13 2009-04-16 Florida Gulf Coast University Optimized dengue virus entry inhibitory peptide (dn81)
US8715689B2 (en) * 2008-04-30 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
SG157244A1 (en) 2008-05-15 2009-12-29 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure or immunity to dengue virus
JP5276941B2 (ja) 2008-09-24 2013-08-28 株式会社村田製作所 大変位アクチュエータ
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
WO2013188315A1 (en) 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
KR101876304B1 (ko) 2009-06-01 2018-07-10 다케다 백신즈 인코포레이티드 뎅기 바이러스에 대한 백신 투여용 조성물 및 방법
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CN101560520A (zh) * 2009-06-04 2009-10-21 中国疾病预防控制中心病毒病预防控制所 乙脑/登革嵌合病毒及其应用
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
MX2015000446A (es) 2012-07-24 2015-03-12 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue.
KR20200067938A (ko) 2012-07-24 2020-06-12 사노피 파스퇴르 백신 조성물
TW201428101A (zh) * 2012-11-08 2014-07-16 Inviragen Inc 登革熱病毒血清型４型之建構物的組成物、方法及用途
JP2016504315A (ja) * 2012-12-14 2016-02-12 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 三価デングウイルス製剤に関する組成物、投与方法および使用
PL3539565T3 (pl) 2013-03-15 2023-09-25 Takeda Vaccines, Inc. Kompozycje i sposoby dla konstruktów chimerycznych wirusa dengi w szczepionkach
TW201620546A (zh) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 疫苗組合物
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017005654A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
EP3442571A1 (en) * 2016-04-13 2019-02-20 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
UA127829C2 (uk) 2017-10-16 2024-01-17 Сірем Інстітьют Оф Індіа Прайвет Лімітед Стабільна ліофілізована імуногенна композиція, яка містить живий атенуйований рекомбінантний флавівірус, спосіб і набір для її отримання та застосування
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Also Published As

Publication number Publication date
PE20211814A1 (es) 2021-09-14
BR112015023635A2 (pt) 2018-06-05
BR122021015503A2 (pt) 2021-12-14
SI4129330T1 (sl) 2024-02-29
US20140302088A1 (en) 2014-10-09
PT3539565T (pt) 2023-04-12
CA3177572A1 (en) 2014-09-25
TWI726312B (zh) 2021-05-01
AU2014235476A1 (en) 2015-09-24
ES2933970T3 (es) 2023-02-15
EP2968516A2 (en) 2016-01-20
EP4129330A1 (en) 2023-02-08
JP6818548B2 (ja) 2021-01-20
UY35489A (es) 2014-10-31
HRP20231581T1 (hr) 2024-03-15
NL301223I2 (nl) 2023-07-26
HK1220359A1 (zh) 2017-05-05
EP3689374A1 (en) 2020-08-05
HUE061507T2 (hu) 2023-07-28
JP2016513970A (ja) 2016-05-19
NZ735336A (en) 2021-04-30
LT4129330T (lt) 2023-12-27
AU2019216724B2 (en) 2021-03-04
US20230181682A1 (en) 2023-06-15
ECSP23013715A (es) 2023-04-28
EP3689374B1 (en) 2022-11-02
PL3539565T3 (pl) 2023-09-25
CN113637086A (zh) 2021-11-12
TW201516147A (zh) 2015-05-01
KR20240014580A (ko) 2024-02-01
CN105451763A (zh) 2016-03-30
WO2014150939A2 (en) 2014-09-25
FIC20230021I1 (fi) 2023-06-27
PH12015502120A1 (en) 2016-01-25
SG11201507460PA (en) 2015-10-29
CN113637694A (zh) 2021-11-12
KR20160002780A (ko) 2016-01-08
KR20220054892A (ko) 2022-05-03
KR102389908B1 (ko) 2022-04-26
CN105451763B (zh) 2021-06-18
CR20150569A (es) 2016-04-01
ES2965652T3 (es) 2024-04-16
FR22C1064I1 (fr) 2023-02-03
NZ630869A (en) 2017-11-24
CA3166063A1 (en) 2014-09-25
CA3177574A1 (en) 2014-09-25
EP4183411A1 (en) 2023-05-24
BR112015023635A8 (pt) 2021-12-14
US9783579B2 (en) 2017-10-10
US10449231B2 (en) 2019-10-22
SG10201913387XA (en) 2020-02-27
DOP2015000232A (es) 2016-02-29
US20170290884A1 (en) 2017-10-12
US20220062375A1 (en) 2022-03-03
BR122021015502A2 (pt) 2021-12-14
FI3539565T3 (fi) 2023-04-19
PE20160027A1 (es) 2016-01-28
HUS2300022I1 (hu) 2023-08-28
CN113637693A (zh) 2021-11-12
US11931399B2 (en) 2024-03-19
WO2014150939A3 (en) 2014-12-31
MX2023000349A (es) 2023-04-24
MX2019003602A (es) 2022-06-27
MY187796A (en) 2021-10-24
CN111778263A (zh) 2020-10-16
AU2014235476B2 (en) 2019-05-16
DK4129330T3 (da) 2023-12-11
EP4129330B1 (en) 2023-09-06
TWI733646B (zh) 2021-07-21
EP3539565B1 (en) 2023-01-11
KR102626270B1 (ko) 2024-01-19
EP2968516B1 (en) 2022-01-12
TW202144573A (zh) 2021-12-01
JP2019146594A (ja) 2019-09-05
AU2019216724A1 (en) 2019-09-05
JP7050031B2 (ja) 2022-04-07
CA2903231A1 (en) 2014-09-25
AR095598A1 (es) 2015-10-28
MX2023000354A (es) 2023-02-13
TW201945545A (zh) 2019-12-01
SG10201913435TA (en) 2020-03-30
EP3539565A1 (en) 2019-09-18
AR123702A2 (es) 2023-01-04
US20200061151A1 (en) 2020-02-27
MX2015012893A (es) 2016-04-04
AU2019216724C1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
PH12015502120A1 (en) Compositions and methods for dengue virus chimeric constructs in vaccines
AR093421A1 (es) Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4
PH12018502175A1 (en) Compositions and methods of vaccination against dengue virus in children and young adults
PH12016502431A1 (en) Composition and methods for administration of vaccines against dengue virus
EP2448410A4 (en) TREATMENT AND PREVENTION OF INFECTIONS WITH THE DENGUE VIRUS
MY150613A (en) Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses
BR112018077540A2 (pt) vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
MX2011008988A (es) Derivados de tienopiridina para el tratamiento y prevencion de infecciones por el virus del dengue.
JP2016501015A5 (ja) デングウイルス血清型４（ｄｅｎ−４）構築物に関する組成物、方法および使用
TN2012000214A1 (en) Hepatitis c virus inhibitors
MY152971A (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
PE20110992A1 (es) Composicion inmunogenica que comprende un antigeno del virus del dengue
MX2015004191A (es) Metodos y reactivos para la deteccion, cuantificacion y serotipado de virus del dengue.
WO2012065105A3 (en) Chimeric flavivirus vaccines
IN2014CN03925A (es)
PH12021550785A1 (en) Virus vaccine
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
WO2016130786A3 (en) Flaviviridae proteins and virions and methods of use thereof
TH170668A (th) องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน
CO2021017772A2 (es) Virus del dengue atenuados
EP2435572A4 (en) RECOMBINANT VIRUSES FROM ANTIGEN CHIMERIC TICK-BORNE ENZEPHALITIS VIRUS AND DENGUE VIRUS TYPE 4
MX350236B (es) Composiciones de peptidos para el tratamiento y diagnostico de la fiebre por virus del dengue.